Cargando…

Massive Release of CD9(+) Microvesicles in Human Immunodeficiency Virus Infection, Regardless of Virologic Control

BACKGROUND: The role of extracellular vesicles (EVs) in human immunodeficiency virus (HIV) pathogenesis is unknown. We examine the cellular origin of plasma microvesicles (MVs), a type of ectocytosis-derived EV, the presence of mitochondria in MVs, and their relationship to circulating cell-free mit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Poveda, Eva, Tabernilla, Andrés, Fitzgerald, Wendy, Salgado-Barreira, Ángel, Grandal, Marta, Pérez, Alexandre, Mariño, Ana, Álvarez, Hortensia, Valcarce, Nieves, González-García, Juan, Bernardino, José Ignacio, Gutierrez, Félix, Fujioka, Hisashi, Crespo, Manuel, Ruiz-Mateos, Ezequiel, Margolis, Leonid, Lederman, Michael M, Freeman, Michael L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Major Articles and Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8922002/ https://www.ncbi.nlm.nih.gov/pubmed/32603406 http://dx.doi.org/10.1093/infdis/jiaa375

Ejemplares similares

Interleukin 18 (IL-18) and IL-3 in Extracellular Vesicles: Biomarkers for Durable Elite Control of HIV-1
por: Poveda, Eva, et al.
Publicado: (2023)

Antiretroviral Treatment for HIV Elite Controllers?
por: Ruiz-Mateos, Ezequiel, et al.
Publicado: (2020)

Virological Outcome Measures During Analytical Treatment Interruptions in Chronic HIV-1-Infected Patients
por: Fehér, Csaba, et al.
Publicado: (2019)

Bronchiolitis, Regardless of Its Etiology and Severity, Is Associated With Increased Risk of Asthma: A Population-Based Study
por: Muñoz-Quiles, Cintia, et al.
Publicado: (2023)

Virological Failure and Acquired Genotypic Resistance Associated With Contemporary Antiretroviral Treatment Regimens
por: Rhee, Soo-Yon, et al.
Publicado: (2020)

Assessment of Virological Contributions to COVID-19 Outcomes in a Longitudinal Cohort of Hospitalized Adults
por: Simons, Lacy M, et al.
Publicado: (2022)

Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks
por: Rolle, Charlotte-Paige, et al.
Publicado: (2023)

Racial Disparities in Virologic Failure and Tolerability During Firstline HIV Antiretroviral Therapy
por: Bhagwat, Priya, et al.
Publicado: (2019)

Clinical and Virologic Characteristics and Outcomes of Coronavirus Disease 2019 at a Cancer Center
por: Yoke, Leah H, et al.
Publicado: (2021)

Virological and Serological Assessment of US Army Trainees Isolated for Coronavirus Disease 2019
por: Hakre, Shilpa, et al.
Publicado: (2022)

Virologic Failure Following Low-level Viremia and Viral Blips During Antiretroviral Therapy: Results From a European Multicenter Cohort
por: Elvstam, Olof, et al.
Publicado: (2022)

Virologic Outcomes Among People Living With Human Immunodeficiency Virus With High Pretherapy Viral Load Burden Initiating on Common Core Agents
por: Mills, Anthony M, et al.
Publicado: (2021)

A Randomized Trial of Dolutegravir Plus Darunavir/Cobicistat as a Switch Strategy in HIV-1-Infected Patients With Resistance to at Least 2 Antiretroviral Classes
por: Santos, José R, et al.
Publicado: (2023)

Durable Sustained Virologic Response After Oral Directly Acting Antiviral Therapy Despite Immunosuppressive Treatment
por: Hahn, Katherine J., et al.
Publicado: (2015)

Risk Factors for Hepatitis C Virus Reinfection After Sustained Virologic Response in Patients Coinfected With HIV
por: Young, Jim, et al.
Publicado: (2017)

Unsatisfactory long-term virological suppression in human immunodeficiency virus-infected children in the Amazonas State, Brazil
por: Pacheco, Ana Luisa Opromolla, et al.
Publicado: (2020)

Results of Early Virologic Monitoring May Facilitate Differentiated Care Monitoring Strategies for Clients on ART, Rakai, Uganda
por: Ssempijja, Victor, et al.
Publicado: (2018)

Beyond Undetectable: Modeling the Clinical Benefit of Improved Antiretroviral Adherence in Persons With Human Immunodeficiency Virus With Virologic Suppression
por: Castillo-Mancilla, Jose R, et al.
Publicado: (2023)

The Effect of Hepatitis C Virologic Clearance on Cardiovascular Disease Biomarkers in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection
por: Chew, Kara W., et al.
Publicado: (2014)

Long-Term Virological Treatment Outcomes in Adolescents and Young Adults With Perinatally and Non-Perinatally Acquired Human Immunodeficiency Virus
por: Weijsenfeld, Annouschka M, et al.
Publicado: (2022)

Virologic Failure and Human Immunodeficiency Virus Drug Resistance in Rural Cameroon With Regard to the UNAIDS 90-90-90 Treatment Targets
por: Boullé, Charlotte, et al.
Publicado: (2016)

Clinical, Virologic, and Immunologic Characteristics of Zika Virus Infection in a Cohort of US Patients: Prolonged RNA Detection in Whole Blood
por: El Sahly, Hana M, et al.
Publicado: (2018)

Prevalence of virological and serological markers of SARS-CoV-2 infection in the population of Ribeirão Preto, Southeast Brazil: an epidemiological survey
por: Martinez, Edson Zangiacomi, et al.
Publicado: (2021)

Association of Incomplete Adherence to Antiretroviral Therapy With Cardiovascular Events and Mortality in Virologically Suppressed Persons With HIV: The Swiss HIV Cohort Study
por: Castillo-Mancilla, Jose R, et al.
Publicado: (2021)

Hepatitis C Virus Reinfection in People With HIV in Taiwan After Achieving Sustained Virologic Response With Antiviral Treatment: The RECUR Study
por: Liu, Chen-Hua, et al.
Publicado: (2022)

Persistence of Human Immunodeficiency Virus-1 Drug Resistance Mutations in Proviral Deoxyribonucleic Acid After Virologic Failure of Efavirenz-Containing Antiretroviral Regimens
por: De La Cruz, Justin, et al.
Publicado: (2019)

Retrospective Study Demonstrating High Rates of Sustained Virologic Response After Treatment With Direct-Acting Antivirals Among American Indian/Alaskan Natives
por: Mera, Jorge, et al.
Publicado: (2019)

Detection of HIV Virologic Failure and Switch to Second-Line Therapy: A Systematic Review and Meta-analysis of Data From Sub-Saharan Africa
por: Bernabé, Kerlly J, et al.
Publicado: (2022)

Impact of Multicomponent Support Strategies on Human Immunodeficiency Virus Virologic Suppression Rates During Coronavirus Disease 2019: An Interrupted Time Series Analysis
por: Spinelli, Matthew A, et al.
Publicado: (2022)

Safety, Virology, Pharmacokinetics, and Clinical Experience of High-Dose Intravenous Sotrovimab for the Treatment of Mild to Moderate COVID-19: An Open-Label Clinical Trial
por: Moya, Jaynier, et al.
Publicado: (2023)

A Randomized Placebo Controlled Trial of Aspirin Effects on Immune Activation in Chronically Human Immunodeficiency Virus-Infected Adults on Virologically Suppressive Antiretroviral Therapy
por: O’Brien, Meagan P., et al.
Publicado: (2017)

Human Immunodeficiency Virus Viral Load Monitoring and Rate of Virologic Suppression Among Patients Receiving Antiretroviral Therapy in Democratic Republic of the Congo, 2013–2020
por: Mayasi Ngongo, Nadine, et al.
Publicado: (2023)

High Rates of Virological Suppression in a Cohort of Human Immunodeficiency Virus-Positive Adults Receiving Antiretroviral Therapy in Ethiopian Health Centers Irrespective of Concomitant Tuberculosis
por: Reepalu, Anton, et al.
Publicado: (2014)

Efficacy and Safety of a Preemptive Antiviral Therapy Strategy Based on Combined Virological and Immunological Monitoring for Active Cytomegalovirus Infection in Allogeneic Stem Cell Transplant Recipients
por: Navarro, David, et al.
Publicado: (2016)

Efficacy of Rilpivirine-Based Regimens as Switch Therapy From Nevirapine-Based Regimens in Human Immunodeficiency Virus-Infected Patients With Virological Suppression: A Randomized Controlled Trial
por: Petchkum, Porkaew, et al.
Publicado: (2019)

A Single Quantifiable Viral Load Is Predictive of Virological Failure in Human Immunodeficiency Virus (HIV)-Infected Patients on Combination Antiretroviral Therapy: The Austrian HIV Cohort Study
por: Leierer, Gisela, et al.
Publicado: (2016)

Virological Characterization of the First 2 COVID-19 Patients Diagnosed in Italy: Phylogenetic Analysis, Virus Shedding Profile From Different Body Sites, and Antibody Response Kinetics
por: Colavita, Francesca, et al.
Publicado: (2020)

Transitioning to Dolutegravir in a Programmatic Setting: Virological Outcomes and Associated Factors Among Treatment-Naive Patients With HIV-1 in the Kilombero and Ulanga Antiretroviral Cohort in Rural Tanzania
por: Ntamatungiro, Alex J, et al.
Publicado: (2023)

Human Immunodeficiency Virus-1 Sequence Changes and Drug Resistance Mutation Among Virologic Failures of Lopinavir/Ritonavir Monotherapy: AIDS Clinical Trials Group Protocol A5230
por: Vardhanabhuti, Saran, et al.
Publicado: (2016)

Efficacy and Safety of Switching to Dolutegravir With Boosted Darunavir in Virologically Suppressed Adults With HIV-1: A Randomized, Open-Label, Multicenter, Phase 3, Noninferiority Trial: The DUALIS Study
por: Spinner, Christoph D, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mf1t5b39u0fc5lebm8kkehvro6